ESC/EAS update clinical guidance on PCSK9

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.

Publication in full

Authors

Ulf Landmesser, M. John Chapman, Jane K. Stock, Pierre Amarenco, Jill J.F. Belch, Jan Borén, Michel Farnier, Brian A Ference, Stephan Gielen, Ian Graham, Diederick E. Grobbee, G. Kees Hovingh, Thomas F. Lüscher, Massimo F. Piepoli, Kausik K. Ray, Erik S. Stroes, Olov Wiklund, Stephan Windecker, Jose Luis Zamorano, Fausto Pinto, Lale Tokgözoğlu, Jeroen J. Bax, Alberico L Catapano on behalf of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Editorial

ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors, by  Jane K. Stock

Slide set

Cookies
We use cookies. If you think that's OK, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings".
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. You can change your settings from our Cookie Policy page.
Save Accept all

Report

Contains abusive or derogatory content
Contains mature or sensitive content
Contains misleading or false information
Contains spam, fake content or potential malware
Harassment or bullying behavior

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .